NIV in Covid-19 Respiratory Failure

Non-invasive Ventilation in Covid-19 Respiratory Failure - Predicting Success: A Retrospective Observational Study to Determine Predictive Factors in the Success or Failure of Non-invasive Ventilation.

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05020691

Enrollment

Registered

2021-08-25

Start date

2021-08-18

Completion date

2021-11-03

Last updated

2023-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Pneumonia

Keywords

Covid-19, HACOR, Non-Invasive Ventilation, CPAP

Brief summary

A retrospective, single centre observational study to validate use of the HACOR score (Duan et al, 2017) in determining efficacy of non-invasive ventilation in Covid-19 respiratory failure.

Detailed description

The investigators will retrospectively analyse medical records of patients with confirmed Covid-19 respiratory failure who received continuous positive airway pressure (CPAP) via facemask, as per clinician decision, in the High Dependency Unit (HDU) or Intensive Care Unit (ICU) of University Hospital Crosshouse between 1st March 2020 and 30th April 2021. By collecting baseline demographics and physiological data (including APACHE II and clinical frailty score) and calculating the HACOR score at initiation of CPAP, then at 1hr, 6hrs, 12hrs, 24hrs and 48hrs after initiating CPAP the investigators aim to validate use of the HACOR score in determining efficacy of NIV in Covid-19 respiratory failure. The investigators will also collect other variables (CRP and lymphocytes, lactate, mean arterial pressure, temperature) to determine if these factors have utility in predicting efficacy of NIV in Covid-19 respiratory failure.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Confirmed Covid-19 respiratory failure 2. NIV treatment instituted as per clinician decision 3. Admitted to HDU or ICU between 1/3/20 and 30/4/21

Exclusion criteria

1. Patients with immediate indication for invasive ventilation 2. Patients whose primary diagnosis was not Covid-19 respiratory failure, but received NIV in that time period

Design outcomes

Primary

Measure	Time frame	Description
Escalation to Invasive Ventilation	Up to 6 months	Number of patients who deteriorated after NIV commenced, requiring escalation to invasive ventilation
Death Due to Respiratory Failure	Up to 6 months	Number of patients who deteriorated after NIV commenced, resulting in death due to respiratory failure
Clinical Improvement	Up to 6 months	Number of patients who improved after NIV commenced, resulting in liberation from NIV (without requiring invasive ventilation)

Countries

United Kingdom

Outcome results